Delving into the Latest Updates on NovoCure GmbH with Synapse

Overview

Tags

Neoplasms

Congenital Disorders

Skin and Musculoskeletal Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Nervous System Diseases	2
Endocrinology and Metabolic Disease	2
Infectious Diseases	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	2

Top 5 Drug Type	Count

Monoclonal antibody	4

Top 5 Target	Count

PD-1(Programmed cell death protein 1)	1
PDL1(Programmed death-ligand 1)	1
VEGFR2(Vascular endothelial growth factor receptor 2)	1
IL-11(interleukin 11)	1

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).

Start Date01 Oct 2024

Sponsor / Collaborator

NovoCure GmbH

[+1]

NL-OMON57019 / SuspendedNot Applicable

LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy - LUNAR-4

Start Date10 Sep 2024

Sponsor / Collaborator

NovoCure GmbH

100 Clinical Results associated with NovoCure GmbH

Login to view more data

0 Patents (Medical) associated with NovoCure GmbH

Login to view more data

81

Literatures (Medical) associated with NovoCure GmbH

01 Apr 2024·Journal of Neuro-Oncology

Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors

Article

Author: Widemann, Brigitte C ; Burton, Eric C ; Butman, John A ; Komlodi-Pasztor, Edina ; Boris, Lisa ; Avgeropoulos, Nicholas G ; Gilbert, Mark R ; Dunbar, Erin M ; Soldatos, Ariane ; Zaghloul, Kareem ; Forsyth, Peter ; Lukas, Rimas V ; Ozer, Byram H ; Chittiboina, Prashant ; Mandel, Jacob ; Dixit, Karan S ; Tsien, Christina I ; Rogers, James L ; Kim, Yeonju ; Snyder, James ; Smith-Cohn, Matthew A ; Ranjan, Surabhi ; Penas-Prado, Marta ; Salacz, Michael E ; Chaudhry, Huma ; Raygada, Margarita ; Aboud, Orwa ; Acquaye-Mallory, Alvina A ; Lee, Eudocia Q ; Heiss, John D ; Wall, Thomas ; Smirniotopoulos, James G ; Cachia, David M ; Drappatz, Jan ; Armstrong, Terri S ; Quezado, Martha M ; Theeler, Brett J ; Aldape, Kenneth ; Camphausen, Kevin A

AbstractPurposeMultidisciplinary tumor boards (MTBs) integrate clinical, molecular, and radiological information and facilitate coordination of neuro-oncology care. During the COVID-19 pandemic, our MTB transitioned to a virtual and multi-institutional format. We hypothesized that this expansion would allow expert review of challenging neuro-oncology cases and contribute to the care of patients with limited access to specialized centers.MethodsWe retrospectively reviewed records from virtual MTBs held between 04/2020–03/2021. Data collected included measures of potential clinical impact, including referrals to observational or therapeutic studies, referrals for specialized neuropathology analysis, and whether molecular findings led to a change in diagnosis and/or guided management suggestions.ResultsDuring 25 meetings, 32 presenters discussed 44 cases. Approximately half (n = 20; 48%) involved a rare central nervous system (CNS) tumor. In 21% (n = 9) the diagnosis was changed or refined based on molecular profiling obtained at the NIH and in 36% (n = 15) molecular findings guided management. Clinical trial suggestions were offered to 31% (n = 13), enrollment in the observational NCI Natural History Study to 21% (n = 9), neuropathology review and molecular testing at the NIH to 17% (n = 7), and all received management suggestions.ConclusionVirtual multi-institutional MTBs enable remote expert review of CNS tumors. We propose them as a strategy to facilitate expert opinions from specialized centers, especially for rare CNS tumors, helping mitigate geographic barriers to patient care and serving as a pre-screening tool for studies. Advanced molecular testing is key to obtaining a precise diagnosis, discovering potentially actionable targets, and guiding management.

08 Dec 2023·Neuro-Oncology

Towards more Diversity in Neuro-oncology Leadership—the DivINe Initiative

Letter

Author: von Baumgarten, Louisa ; Grosu, Anca-L ; McLean, Anna ; Albert, Nathalie L ; Hegi, Monika ; Rosahl, Steffen K ; Sevenich, Lisa ; Gempt, Jens ; Tabatabai, Ghazaleh ; Combs, Stephanie E ; Schwarzenberger, Julia ; Abrey, Lauren E ; Stammberger, Anja ; Renovanz, Mirjam ; Nowosielski, Martha ; Leidgens, Verena ; Urbanic Purkart, Tadeja ; Kurz, Sylvia C

10 Nov 2023·Neuro-Oncology

QOL-19. TUMOR TREATING FIELDS (TTFIELDS) THERAPY IN GLIOBLASTOMA (GBM): RELATIONSHIP BETWEEN PATIENT EXPERIENCE, GLOBAL REGION, AND AGE

Author: Batzianouli, Eleni ; Shockley, Shermona ; Johnson, Heather ; Gage Gwyn, P ; Abdullah, Huda Ismail ; Adams, Renae

AbstractBACKGROUNDTTFields therapy is a noninvasive, locoregional anticancer treatment approved for newly diagnosed and recurrent GBM based on efficacy and safety results in 2 global, randomized pivotal studies, supported by real-world evidence.METHODSIn 2022, 2 questionnaires (mail or online) surveyed the real-world experiences of patients with GBM receiving TTFields therapy (NovoTTF-200A; Novocure®, GmBH) and their caregivers in Germany, Austria, and Switzerland (DACH), and the USA.RESULTS545/1197 surveys were returned in DACH (46%); 1332/5031 in the USA (26%). Most respondents indicated satisfaction/high satisfaction with TTFields (in patients starting therapy, 82% [DACH] and 58% [USA]; in patients with >6 months use, 67% [DACH] and 72% [USA]). The following data pertain to patients with >6 months of TTFields use (n = 114 DACH; n = 375 USA). 63% in DACH reported that daily life was changed “much”/“very much”, and 35% “hardly at all”; in the USA, 17% indicated they were able to live as they did before therapy, 61% had to make adjustments but had returned to a normal routine, and 23% said therapy had markedly impacted daily life. 74% (DACH) and 73% (USA) would recommend to other patients. Common reasons for low satisfaction included skin irritation and device handling. To assess any impact of age, responses from patients aged ≥70 years ( >6 months use) from the USA (n = 82 [22%]) were analyzed (there were not enough elderly patients with >6 months use in DACH [n = 8] to analyze). As with the overall population, elderly patients in the USA reported they were satisfied/very satisfied (67%). 66% of elderly patients (USA) were very likely to recommend TTFields to someone else.CONCLUSIONSSurveys of patient/caregivers in DACH and the USA who used TTFields for GBM identified a high degree of satisfaction, including elderly patients. Most respondents would recommend TTFields to others.

100 Deals associated with NovoCure GmbH

Login to view more data

100 Translational Medicine associated with NovoCure GmbH

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

1

Phase 2 Clinical

Phase 3 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Pembrolizumab ( PD-1 )	Glioblastoma More	Phase 3
Atezolizumab ( PDL1 )	Metastatic Pancreatic Ductal Adenocarcinoma More	Phase 2
WO2024141995 ( VEGFR2 )	Neoplasms More	Discovery
TW202216191 ( IL-11 )	Neoplasms More	Discovery